Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.

MLA

Rivero, Antonio, et al. “Costs and Cost-Efficacy Analysis of the 2017 GESIDA/Spanish National AIDS Plan Recommended Guidelines for Initial Antiretroviral Therapy in HIV-Infected Adults.” Enfermedades Infecciosas y Microbiologia Clinica (English Ed.), vol. 36, no. 5, May 2018, pp. 268–76. EBSCOhost, https://doi.org/10.1016/j.eimc.2017.04.002.

APA

Rivero, A., Pérez-Molina, J. A., Blasco, A. J., Arribas, J. R., Asensi, V., Crespo, M., Domingo, P., Iribarren, J. A., Lázaro, P., López-Aldeguer, J., Lozano, F., Martínez, E., Moreno, S., Palacios, R., Pineda, J. A., Pulido, F., Rubio, R., Santos, J., de la Torre, J., … Gatell, J. M. (2018). Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enfermedades Infecciosas y Microbiologia Clinica (English Ed.), 36(5), 268–276. https://doi.org/10.1016/j.eimc.2017.04.002

Chicago

Rivero, Antonio, José Antonio Pérez-Molina, Antonio Javier Blasco, José Ramón Arribas, Víctor Asensi, Manuel Crespo, Pere Domingo, et al. 2018. “Costs and Cost-Efficacy Analysis of the 2017 GESIDA/Spanish National AIDS Plan Recommended Guidelines for Initial Antiretroviral Therapy in HIV-Infected Adults.” Enfermedades Infecciosas y Microbiologia Clinica (English Ed.) 36 (5): 268–76. doi:10.1016/j.eimc.2017.04.002.